Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF‐κB pathway

OBJECTIVES: The main target of current drugs for alleviating bone loss is osteoclasts. However, the long‐term application of such drugs will also cause side effects. Therefore, it is of great need to develop new and safer therapeutics for osteoporosis. In recent years, drug development based on gut...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yajun, Zhuang, Qi, Tao, Lihong, Zheng, Kai, Chen, Shuangshuang, Yang, Yunshang, Feng, Chengcheng, Wang, Zhifang, Shi, Haiwei, Shi, Jiandong, Fang, Yiling, Xiao, Long, Geng, Dechun, Wang, Zhirong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528769/
https://www.ncbi.nlm.nih.gov/pubmed/35708050
http://dx.doi.org/10.1111/cpr.13291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528769/
https://www.ncbi.nlm.nih.gov/pubmed/35708050
http://dx.doi.org/10.1111/cpr.13291

Ejemplares similares